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Abstract
Aims/hypothesis We compared the effects of insulin degludec
(IDeg; Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human
insulin) and insulin glargine (IGlar; A21Gly,B31Arg,
B32Arg human insulin) on the day-to-day variability of
fasting plasma glucose (FPG) levels in individuals with type
1 diabetes treated with basal-bolus insulin injections.
Methods The effects of basal-bolus insulin therapy for
4 weeks with either IDeg or IGlar as the basal insulin in adult
C-peptide-negative outpatients with type 1 diabetes were in-
vestigated in an open-label, multicentre, randomised, cross-
over trial. Randomisation was conducted using a centralised
allocation process. The primary endpoints were the SD and
CV of FPG during the final week of each treatment period.
Secondary endpoints included serum glycoalbumin level, dai-
ly dose of insulin, intraday glycaemic variability and frequen-
cy of severe hypoglycaemia.
Results Thirty-six randomised participants (17 in the
IDeg/IGlar and 19 in the IGlar/IDeg groups) were recruited,
and data for 32 participants who completed the trial were
analysed. The mean (7.74±1.76 vs 8.56±2.06 mmol/l; p=
0.04) and SD (2.60±0.97 vs 3.19±1.36 mmol/l; p=0.03) of
FPG were lower during IDeg treatment than during IGlar
treatment, whereas the CV did not differ between the two
treatments. The dose of IDeg was smaller than that of IGlar
(11.0±5.2 vs 11.8±5.6 U/day; p<0.01), but other secondary
endpoints did not differ between the treatments.
Conclusions/interpretation IDeg yielded a lower FPG level
and smaller day-to-day variability of FPG at a lower daily
dose compared with IGlar in participants with type 1 diabetes.
IDeg serves as a good option for basal insulin in the treatment
of type 1 diabetes.
Trial registration: University Hospital Medical Information
Network 000009965.
Funding: This research recieved no specific grant from any
funding agency in the public, commercial or not-for-profit sectors.
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SMBG Self-monitoring of blood glucose
Introduction
The basal secretion of insulin during the fasting state plays an
essential role inmaintaining an appropriate level of endogenous
glucose production, and the additional secretion of the hormone
after a meal is critical for the anabolism and storage of this
energy source. Individuals with type 1 diabetes, in whom insu-
lin secretion is greatly impaired, must therefore supplement
their endogenous insulin by a basal-bolus administration of
exogenous hormone in order to mimic the physiological regu-
lation of energy metabolism and improve glycaemic control.
In patients with type 1 diabetes who undergo basal-bolus
insulin therapy with multiple daily injections, basal insulin is
largely responsible for the stability of blood glucose levels in
the fasting state. Insulin glargine (IGlar; A21Gly,B31Arg,
B32Arg human insulin) is a long-acting insulin analogue that
is widely administered as a basal insulin in basal-bolus thera-
py. IGlar exhibits a longer and flatter temporal pattern of hor-
mone action than NPH insulin, with a duration of biological
action of ∼24 h [1]. Evidence suggest that basal-bolus therapy
for patients with type 1 diabetes using IGlar has been associ-
ated with a reduced number of daily injections [2, 3], a re-
duced frequency of hypoglycaemia [3–7], a reduced variabil-
ity of fasting plasma glucose (FPG) concentration [2] and
lower FPG and HbA1c levels [4, 6–9] relative to NPH insulin,
which is indicative of the benefits of IGlar for such therapy.
Insulin degludec (IDeg; Des(B30)LysB29(γ-Glu Nε-
hexadecandioyl) human insulin) is a novel ultra-long-acting
insulin analogue that was first launched in the UK in January
2013 and is now available in several European and Asian
countries including Japan. The duration of action for IDeg,
estimated at ∼42 h [10], is much longer than that for IGlar.
Such pharmacokinetics are attributable both to the slower ab-
sorption of IDeg from the injection site into the circulation as a
result of its formation of soluble multihexameric chains and to
its prolonged retention in the circulation as a result of its bind-
ing to albumin in the blood [11]. Clinical studies have re-
vealed that basal-bolus therapy with IDeg is associated with
a similar level of glycaemic control [12, 13], a lower daily
dose [13, 14] and less frequent nocturnal hypoglycaemia
[12–14] in individuals with type 1 diabetes in comparison
with IGlar. The frequency of nocturnal hypoglycaemia has
been shown to be related to the variability of FPG levels
[15]. Moreover, a euglycaemic glucose clamp analysis has
revealed a lower variability in pharmacodynamics for IDeg
than for IGlar [16]. Treatment with IDeg might thus be ex-
pected to result in lower day-to-day variability in the glucose-
lowering effect of basal-bolus therapy. There has, however,
been no clinical study to date that has directly evaluated this
possibility.
We performed the current study to investigate the day-to-
day variability of the glucose-lowering effect of IDeg. We
compared the SD and CV of FPG levels in individuals with
type 1 diabetes treated with basal-bolus insulin therapy using
either IDeg or IGlar.
Methods
This study was conducted in accordance with the Declaration
of Helsinki and was approved by the local institutional review
boards of the participating centres. Written informed consent
was obtained from all participants before beginning the trial,
which has been registered with the University Hospital
Medical Information Network (UMIN 000009965). The study
was an open-label, randomised, multicentre, crossover trial
designed to investigate the day-to-day variability of FPG in
participants with type 1 diabetes treated with basal-bolus in-
sulin therapy using either IDeg or IGlar as the basal insulin.
The participating centres and principal investigators for the
trial are listed in the Appendix.
Inclusion criteria for the trial included: (1) individuals with
type 1 diabetes who were at least 18 years of age and whose
serum C-peptide concentration had been confirmed to be be-
low detectable levels (<0.07 nmol/l) at least twice; (2) indi-
viduals who had been treated for at least 1 year with basal-
bolus insulin injections with IGlar as the basal insulin and a
rapid-acting insulin analogue or regular insulin as the bolus
insulin; (3) individuals with the ability to perform self-
monitoring of blood glucose (SMBG); and (4) individuals
with an HbA1c level of ≤8% (64 mmol/mol). The exclusion
criteria included: (2) the use of medications that affect glucose
metabolism (such as beta-blockers, corticosteroids and mono-
amine oxidase inhibitors); (2) a history of myocardial infarc-
tion, angina pectoris, coronary artery bypass surgery or heart
failure within the preceding 6 months; (3) severe hypertension
(systolic BP of ≥180 mmHg or diastolic BP of ≥100 mmHg);
(4) severe liver dysfunction (serum aspartate aminotransferase
or alanine aminotransferase levels of ≥2.5 times the normal
upper limit); (5) severe renal dysfunction (a serum creatinine
concentration of ≥177 μmol/l); (6) the presence of antibodies
to insulin that might influence the variability of plasma glu-
cose levels; (7) frequently recurring severe hypoglycaemia or
hospitalisation due to serious hypoglycaemia or diabetic
ketoacidosis within the previous year; (8) the complication
of proliferative diabetic retinopathy with a high risk of haem-
orrhage; (9) existing or possible pregnancy or breastfeeding;
(10) the presence of cancer; (11) a complicating psychiatric
disorder; (12) alcoholism or other drug addiction; and (13) an
investigator’s declaration that the participant was otherwise
inappropriate for the study. Insulin antibodies were checked
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for all participants as part of the screening procedure. Severe
hypoglycaemia was defined as events associated with central
nervous system manifestations during which the patient re-
quired the assistance of another person. The judgement of
frequent recurrence of hypoglycaemia was made by each at-
tending physician.
Individuals found to satisfy the criteria were randomly
assigned to the IGlar (first period)/IDeg (second period)
(IGlar/IDeg) or the IDeg (first period)/IGlar (second period)
(IDeg/IGlar) group by a centralised allocation process. In the
IGlar/IDeg group, the basal insulin was switched after 4 weeks
from IGlar (Lantus, SoloSTAR; Sanofi, Paris, France) to IDeg
(Tresiba, FlexTouch; NovoNordisk, Bagsvaerd, Denmark). In
the IDeg/IGlar group, the basal insulin was switched after
4 weeks from IDeg to IGlar. The participants were directed
to determine their plasma glucose level four times a day (be-
fore breakfast, lunch and dinner as well as at bedtime) by
SMBG during the entire trial period. The last week of each
treatment period constituted the data collection phase, during
which the participants were directed to determine their plasma
glucose level seven times a day (before breakfast, 2 h after
breakfast, before lunch, 2 h after lunch, before dinner, 2 h after
dinner and at bedtime) (Fig. 1). All individuals were provided
with the same device (OneTouch Ultra; Johnson & Johnson,
New Brunswick, NJ) and directed to perform blood testing
with it. Given that the measurements of the SMBG device
are calibrated to the plasma glucose concentrations, we con-
sidered the values recorded by this device as the plasma glu-
cose levels. The serum glycoalbumin level was measured at
the end of each treatment period.
Basal insulin was administered at the same time of day in
both treatment periods. The initial dose of IDeg was equiva-
lent to 80% of the IGlar dose that had been administered
before the start of the trial. Insulin titration was then performed
according to the attending physician’s instruction or the
patient’s own judgement to achieve the target plasma glucose
level. The type of bolus insulin preparation was not changed
during the trial, and the preprandial bolus insulin dose was
adjusted by each participant. The target plasma glucose level
before breakfast, lunch and dinner as well as at bedtime was
initially <7.21 mmol/l and was subsequently reduced to
<6.11mmol/l for individuals capable of achieving a reduction.
The participants were directed to avoid hypoglycaemia
(<3.89 mmol/l) at any time during the day.
The primary endpoint of the study was the day-to-day var-
iability of FPG level as evaluated by the SD and CV of the
plasma glucose level determined by SMBG before breakfast
during the last week of each 4 week treatment period (Fig. 1).
Secondary endpoints included the serum glycoalbumin level
on the final day of each treatment period, the administered
insulin dose (the mean for the last week of each treatment
period), the intraday glycaemic variability calculated from
the seven daily measurements of plasma glucose during the
final week of each treatment period, and the frequency of
severe hypoglycaemic events (defined as events associated
with central nervous system manifestations during which the
patient required the assistance of another person).
To determine the sample size, we performed a preliminary
analysis of the day-to-day variability of FPG in individuals
with type 1 diabetes treated with basal-bolus insulin therapy
including IGlar as the basal insulin at Kobe University
Hospital. The mean CV and mean SD of the CV of FPG for
34 participants over 7 days were 36.1% and 16.5%, respec-
tively. The number of individuals for whom a 30% alteration
of the mean CV could be detected with an α value of 0.05 and
with a statistical power of 80% was 32. We assumed that 10%
of those recruited might drop out from the trial and therefore
determined the total number of participants required to be 36.
We evaluated normal distributions of the data with the use
of Shapiro–Wilk test, and non-normally distributed data were
Randomisation Crossover End of trialScreening
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Data collection Data collection
Fig. 1 Study design. Eligible patients were randomly allocated to the
IGlar/IDeg group (upper arm) or the IDeg/IGlar group (lower arm). In
the IGlar/IDeg group, the basal insulin was switched after 4 weeks from
IGlar to IDeg, whereas in the IDeg/IGlar group the basal insulin was
switched after 4 weeks from IDeg to IGlar. The last week of each
treatment period constituted the data collection phase in which seven
SMBG measurements per day were performed and the insulin dosage
was determined. The serum glycoalbumin level was also measured on
the last day of each treatment period
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transformed to satisfy the normality assumption by Box–Cox
transformation. Data are presented as means±SD and were
analysed with repeated-measures ANOVA and Grizzle’s mod-
el for a 2×2 crossover study. In these statistical methods, the
values are analysed in a paired manner, using each patient as
their own control. The statistical analyses were performed
using the SPSS version 22 software package (IBM, Armonk,
NY, USA). A p value <0.05 was considered statistically
significant.
Results
The total of 36 randomised participants consisted of 19 indi-
viduals in the IGlar/IDeg group and 17 individuals in the
IDeg/IGlar group. Three participants in the IDeg/IGlar group
did not want to change their insulin preparation at the time of
crossover, and they withdrew consent for participation in the
study at this time. One participant in the IGlar/IDeg group
who initially agreed to participate in the study during the
screening period withdrew consent at the beginning of the first
period of allocated insulin administration. These four partici-
pants were excluded, so a total of 32 participants who com-
pleted the trial were therefore included in the analysis. The
clinical characteristics of these 32 participants are shown in
Table 1.
At the start of the trial, the mean total daily dose of insulin
was 32.7±12.4 U/day, the mean daily dose of basal insulin
was 12.1±5.9 U/day, and the mean daily dose of bolus insulin
was 20.9±8.8 U/day. The number of participants who
administered IGlar in the morning, at noon, in the evening
and at bedtime was 9, 6, 3 and 14, respectively.
We first examined interaction effects (periods and carry-
over effects) for the mean, SD and CV of FPG with
repeated-measures ANOVA and Grizzle’s model for a 2×2
crossover study, and found no interaction effects between
the two intervention periods (p=0.22, 0.44 and 0.80,
respectively).
The mean FPG level determined before breakfast during
the data collection phase was significantly lower in the IDeg
administration period than in the IGlar administration period
(7.74±1.76 vs 8.56±2.06 mmol/l; p=0.04) (Fig. 2a, b). The
SD of FPG was also significantly smaller during IDeg admin-
istration than during IGlar administration (2.60±0.97 vs 3.19±
1.36 mmol/l; p=0.03) (Fig. 2c, d). The CV of FPG did not,
however, differ between the two treatment periods (34.3±13.3
vs 37.1±13.0% for IDeg and IGlar, respectively; p=0.32)
(Fig. 2e, f).
The mean of the seven daily plasma glucose measurements
was significantly lower during the IDeg administration period
than the IGlar administration period (8.30±1.50 vs 9.13±
1.92 mmol/l; p<0.01). Among the seven measurement points,
a significant difference between the two treatment periods was
apparent only for that before breakfast. The intraday SD
(3.39±0.94 vs 3.13±0.85 mmol/l for IGlar and IDeg) and
intraday CV (38.2±9.2 vs 37.6±8.1% for IGlar and IDeg)
for the seven measurements were similar in the two treatment
periods ( p=0.16 and 0.64, respectively).
To further analyse the plasma glucose variability during the
two treatment periods, we calculated the SD of all the plasma
glucose values from all the days of the last week of treatment
(SDT), the SD of the daily means of plasma glucose (SDdm)
and the SD between days within specified time points aver-
aged over all times of day (SDb) (Table 2), as have been
previously used to evaluate glucose variability [17]. We also
calculated the mean difference in plasma glucose values be-
fore and after breakfast [mean(|Δab–bb|)], lunch [mean(|Δal–
bl|)] and dinner [mean(|Δad–bd|)], the mean difference in plas-
ma glucose values before and after all meals [(mean(|Δoverall
average|)] and the mean difference between the bedtime plasma
glucose and FPG [mean(|Δbb–b|)] (Table 2). Of these vari-
ables, only SDT was significantly smaller for IDeg than for
IGlar (3.85±0.91 vs 3.47±0.86 mmol/l for IGlar and IDeg,
respectively; p=0.04). The serum glycoalbumin level was al-
so similar for the two treatment periods (21.8±3.6 vs 21.5±
3.0% for IGlar and IDeg, respectively; p=0.40). No episodes
of severe hypoglycaemia occurred during the entire trial
period.
The total daily dose of insulin was slightly lower in the
IDeg administration period than in the IGlar administration
period, although this difference was not statistically signifi-
cant (31.2±11.4 vs 31.9±11.9 U/day; p=0.15). The daily dose
of basal insulin in the IDeg period was slightly but
Table 1 Clinical char-
acteristics of the partici-
pants according to study
group
Variable
Number of participants 32
Age (years) 57±14
Male/female 13/19













Data for continuous variables are
means±SD
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significantly lower than that in the IGlar period (11.0±5.2 vs
11.8±5.6 U/day; p<0.01). The daily dose of bolus insulin was
similar in the two treatment periods (20.5±8.5 vs 20.5±8.6
U/day for IGlar and IDeg, respectively; p=0.68). During the
study period, severe hypoglycaemia or other notable adverse
effects including skin rash, liver or kidney dysfunctions, ab-
normalities in electrolytes or in completely blood count were
not reported.
Discussion
The primary endpoints of this study were the SD and CV of
FPG during treatment with IDeg and IGlar in a randomised
crossover trial in individuals with type 1 diabetes who
underwent basal-bolus insulin therapy. We have shown here
that the SD of FPG levels was smaller during treatment with
IDeg than with IGlar. The CVof FPG did not, however, differ
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Fig. 2 Mean and variability of
FPG levels. The mean (a), SD (c)
and CV (e) of FPG levels during
the IGlar and IDeg treatment
periods were determined for each
participant. The two data points
for a particular individual were
connected by a line. Horizontal
bars represent the corresponding
mean values for all participants.
Box plots of the mean (b), SD (d)
and CV (f) of FPG are shown.
The line within each box
represents the median, and the top
and bottom of the box represent
the 75th and 25th percentiles,
respectively. The whiskers
indicate the maximum and
minimum values. *p<0.05. NS,
not significant
Table 2 Variables for glycaemic variability
n IGlar IDeg p values
SDT (mmol/l) 32 3.85±0.91 3.47±0.86 0.04
SDdm (mmol/l) 32 2.04±1.07 1.78±0.65 0.25
SDb (mmol/l) 32 3.29±1.05 3.00±0.80 0.10
Mean(|Δab–bb|) (mmol/l) 17 3.42±1.38 3.84±1.94 0.34
Mean(|Δal–bl|) (mmol/l) 22 4.20±2.78 3.62±1.54 0.44
Mean(|Δad–bd|) (mmol/l) 21 4.54±2.66 3.46±1.27 0.11
Mean(|Δoverall average|) (mmol/l) 23 4.25±2.08 3.87±1.17 0.49
Mean(|Δbb–b|) (mmol/l) 28 4.08±1.43 4.24±1.84 0.76
Data are means±SD
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mean value for the IDeg treatment period. Given that the FPG
concentration is greatly influenced by the action of basal in-
sulin, our results indicate that day-to-day variability in the
glucose-lowering effect of IDeg is smaller than that for
IGlar. Clinical trials that have compared the efficacy of IDeg
with that of IGlar have revealed a lower frequency of noctur-
nal hypoglycaemia during IDeg treatment, whereas the fre-
quency of hypoglycaemia during the daytime was similar dur-
ing treatment with IDeg and IGlar [13, 14]. The variability in
FPG levels is closely related to the frequency of nocturnal
hypoglycaemia in patients with type 1 and type 2 diabetes
[15]. It is thus possible that the reduced frequency of nocturnal
hypoglycaemia observed during IDeg treatment in previous
studies is attributable to the low variability of the glucose-
lowering effect of this insulin analogue revealed by the present
study.
Although we set the same target plasma glucose level dur-
ing both treatment periods, the FPG concentration was lower
during IDeg treatment than IGlar treatment, whereas the daily
dose of basal insulin was smaller during IDeg treatment. We
cannot completely exclude the possibility that these observa-
tions are attributable to incidental bias. However, lower FPG
levels achievedwith a lower daily dose of basal insulin in spite
of the same plasma glucose target were also apparent during
treatment with IDeg in comparison with IGlar in a previous
study [13]. The pharmacological characteristics of IDeg may
thus contribute to these observations. In the present study, the
participants themselves titrated the dose of basal insulin in
order to achieve the target FPG level. If the variability of the
glucose-lowering effect is small, it is easier to titrate the dose
of basal insulin in order to maintain the FPG close to the target
level. Moreover, the temporal pattern of the biological action
of IDeg has been found to be flatter than that of IGlar [16],
which might also be related to the reduced frequency of noc-
turnal hypoglycaemia that was observed during treatment with
IDeg [13, 14]. The ‘peak-less’ characteristic of the pharmaco-
kinetics of IDeg might thus allow patients to achieve the target
FPG level with a smaller dosage. In this regard, the proportion
of participants who achieved the primary target plasma glu-
cose level (<7.21 mmol/l) tended to be higher during IDeg
treatment than IGlar treatment (44% and 25%, respectively),
although this difference was not statistically significant ( p=
0.19). In this study, the total basal dose was approximately
35% (35.9% and 34.6% for IGlar and IDeg, respectively) of
the total daily dose at the end of each treatment period. This
percentage was lower than that previously reported for white
individuals with type 1 diabetes, but was similar to those re-
ported for Japanese patients with type 1 diabetes [18, 19].
In the present study, we recruited only participants with
type 1 diabetes whose serum C-peptide level was below the
limit of detection, given that the pharmacology of basal insulin
is well reflected by the plasma glucose level in such individ-
uals. Moreover, all the participants in our study were non-
obese Japanese adults.Whether the results of the present study
are applicable to patients whose capacity for insulin secretion
is not completely exhausted or to those with different physical
constitutions or ethnicities thus remains to be determined.
The current study has some limitations. First, this trial was
an open-label study, and we could not exclude possible biases
induced by recognition of the insulin preparations. Moreover,
the injection devices were different for each of the insulin
preparations. Given that all the participants had used IGlar
before the study, they were familiar with IGlar and had to
familiarise themselves with the IDeg. We cannot exclude the
possibility that this may have introduced some bias into the
study. Finally, the proportions of patients who achieved the
target FPG levels were low in both treatment periods.
In summary, our results indicate that the day-to-day vari-
ability in glucose-lowering effect is smaller for IDeg than for
IGlar. The current result might be related to a lower frequency
of nocturnal hypoglycaemia in individuals with type 1 diabe-
tes who use IDeg as basal insulin [12–14]. It remains to be
elucidated whether the insulin preparation has beneficial ef-
fects on long-term glycaemic control and on diabetic
complications.
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